Biotek-snakken — Marts 2022
-
-
Orphazyme trækker ansøgning for Arimoclomol i Europa - NY https://proinvestor.com/investornyt/798629/orphazyme-traekker-ansogning-for-arimoclomol-i-europa-ny
-
-
Prior to these latest data, one expert had told FirstWord “so far the only thing we hear are excuses why it is not as good as it should be. It may be only a poor development strategy, but it could also be that the drug is not as good as expected. We’ve also had negative trials with other drugs targeting the folate receptor, which were close to registration but in the end failed. I’m still not convinced of this approach."
-
Kort video: Jeg orienterer om overflytningen af ProInvestor til en ny platform. Der lys forude. :−) I disse tider med krig, rentestigninger osv. kan det være svært at navigere som aktieinvestor. Jeg guider til gode input ift. situationen i Ukraine og Rusland og inspiration til, hvad man kan gøre med sin portefølje i en svær tid, med Hans-Henrik Nielsen fra Markettimer. https://www.proinvestor.com/boards/102348
-
SUPPORT-ABONNEMENT - Støt Proinvestor.com: https://www.proinvestor.com/donation
-
NBI ved at bunde ud https://www.proinvestor.com/boards/102420/NBI-ved-at-bunde-ud
-
Biotech Stocks Facing FDA Decision In April 2022 https://proinvestor.com/investornyt/801042/biotech-stocks-facing-fda-decision-in-april-2022
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind